错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Engineered T cell therapy for central nervous system injury

  • Wenqing Gao,
  • Min Woo Kim,
  • Taitea Dykstra,
  • Siling Du,
  • Pavle Boskovic,
  • Cheryl F. Lichti,
  • Miguel A. Ruiz-Cardozo,
  • Xingxing Gu,
  • Tal Weizman Shapira,
  • Justin Rustenhoven,
  • Camilo Molina,
  • Igor Smirnov,
  • Yifat Merbl,
  • Wilson Z. Ray,
  • Jonathan Kipnis

摘要

Traumatic injuries to the central nervous system (CNS) afflict millions of individuals worldwide1, yet an effective treatment remains elusive. Following such injuries, the site is populated by a multitude of peripheral immune cells, including T cells, but a comprehensive understanding of the roles and antigen specificity of these endogenous T cells at the injury site has been lacking. This gap has impeded the development of immune-mediated cellular therapies for CNS injuries. Here, using single-cell RNA sequencing, we demonstrated the clonal expansion of mouse and human spinal cord injury-associated T cells and identified that CD4+ T cell clones in mice exhibit antigen specificity towards self-peptides of myelin and neuronal proteins. Leveraging mRNA-based T cell receptor (TCR) reconstitution, a strategy aimed to minimize potential adverse effects from prolonged activation of self-reactive T cells, we generated engineered transiently autoimmune T cells. These cells demonstrated notable neuroprotective efficacy in CNS injury models, in part by modulating myeloid cells via IFNγ. Our findings elucidate mechanistic insight underlying the neuroprotective function of injury-responsive T cells and pave the way for the future development of T cell therapies for CNS injuries.